Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-05-26
1995-12-12
Rizzo, Nicholas
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514253, 514320, 514324, 514433, 514456, 540575, 544295, 544376, 546196, 546202, 546204, 546181, 546169, 546170, 546176, 549401, 549403, 549405, 549 23, C07D30730, C07D40902, A61K 3150, A61K 31445
Patent
active
054749948
ABSTRACT:
This invention provides bicyclic heterocyclic derivatives and their pharmaceutically acceptable salts useful for the treatment of hypertension, urethral and lower urinary tract contractions, and other disorders. The compounds are also useful for binding .alpha..sub.1 -adrenergic and 5HT.sub.1A serotonergic receptors, in vitro or in vivo.
REFERENCES:
patent: 2921070 (1960-01-01), Da Re
patent: 3277094 (1966-10-01), Werner
patent: 3350411 (1967-10-01), Da Re
patent: 3810896 (1974-05-01), Witte et al.
patent: 4089969 (1978-05-01), Muchowski et al.
patent: 4495198 (1985-01-01), Wu
patent: 4539318 (1985-09-01), Baldwin et al.
patent: 4668804 (1987-05-01), Wu
patent: 4668805 (1987-05-01), Wu
patent: 4684651 (1987-08-01), Kikumoto et al.
patent: 4797498 (1989-01-01), Albrecht et al.
patent: 4940711 (1990-07-01), Nardi et al.
patent: 5019182 (1992-02-01), Ong et al.
patent: 5403847 (1995-04-01), Gluchowski et al.
Derwent Abstract C93-164399 (From Reference A) (1993).
Paolo Da Re et al. Jahrg, 99:1962-1965, (1966).
Robert A. Lyon et al. J. Med. Chem., 29:630-634, (1986).
Gregory E. Martin et al. J. Med. Chem., 32:1052-1056, (1989).
Wolter ten Hoeve et al. J. Org. Chem., 58:5101-5105, (1993).
Atassi et al., Eur. J. Med. Chem., 20:393-402 (1985).
Augstein et al., J. Med. Chem., 8:356-367 (1965).
Bagli, J. Med. Chem., 19:876-882 (1976).
Bonte et al., Eur. J. Med. Chem., 25:361-368 (1990).
Carroll et al., J. of Med. Chem., 19(9):1111-1119 (1976).
Cunico et al., Org. Chem., 48:2780-2782 (1983).
Da Re, P. et al. Jahrg, 99:1962-1965, (1966).
Da Re, Ann. Chim., pp. 506-513 (1962).
Da Re et al., Eur. J. Med. Chem., 13:387-388 (1978).
Da Re, Il Farmaco-Ed. Sc., vol. XI:670-675 (1960).
Da Re et al., J. Med. Chem., 2(3):263-269 (1960).
Engel et al., J. Med. Chem., 33:2976-2981 (1990).
Farina et al., Biochem. Pharm., 31:1887-1892 (1982).
Farina et al., Biochem. Pharm., 35:209-215 (1986).
Frishman et al., Cardiovascular Pharmacotherapy II, 72(2):427-440 (1988).
Garcia-Sainz et al., Biochemical and Biophysical Research Communications, 186(2):760-767 (1992).
Gartside et al., European Journal of Pharmacology, 191:391-400 (1990).
Grewal et al., J. Pharmac. Exp. Therap., 160(2):268-276 (1968).
Guarneri et al., Neurourol. Urodyn., 11:340-41 (1992).
Hamon et al., Annals New York Academy of Sciences, pp. 114-131 (1960).
Hartig et al., Drug Delivery Res., 26(3):215-224 (1992).
Laubie et al., Arzheim-Forsch, 19:1820-1826 (1969).
Leclerc et al., Arzheim-Forsch Drug. Res., 35:1357-1367 (1985).
Lyon, R. A. et al. J. Med. Chem., 29:630-634, (1986).
Martin, G. E. et al. J. Med. Chem., 32:1052-1056, (1989).
Mielke et al., Curr. Therap. Res., 15(6):324-326 (1973).
Mull et al., J. Med. Chem., 8:332-338 (1965).
Overberger et al., J.A.C.S., 71:2661-2666 (1949).
Perez et al., Molecular Pharmacology, 40:876-883 (1991).
Ratouis et al., J. Med. Chem., 8:271-273 (1965).
Ratouis et al., J. Med. Chem., 8:104-107 (1965).
Romero et al., Annual Reports in Medical Chemistry, 27(3):21-30 (1992).
Saari et al., J. Med. Chem., 33:97-101 (1990).
Silvestrini et al., Arzheim-Forsch./Drug. Res., 32:668-673 (1982).
ten Hoeve, W. et al. J. Org. Chem., 58:5101-5105, (1993).
Traber et al., TIPS, 8:432-437 (1987).
Uneyama et al., Bull. Chem. Soc. Jpn., 58:2361-2365 (1985).
Valenti et al., Boll. Chim. Farm., 114:294-300 (1975).
Vizi et al., Medicinal Research Reviews, 6:431-449 (1986).
Wu et al., J. Med. Chem., 35:3519-3525 (1992).
Zifa et al., Pharmacological Reviews, 44(3):401-458 (1992).
Drugs of the Future, 6:346-347 (1981).
Chemical Abstracts 55:5534a (1960).
Chemical Abstracts 59:2832b (1963).
Chemical Abstracts 63:11589h (1965).
Chemical Abstracts 66:37693s (1967).
Chemical Abstracts 66:85664e (1967).
Chemical Abstracts 67:64435m (1967).
Chemical Abstracts 74:22698p (1971).
Chemical Abstracts 76:14577z (1972).
Chemical Abstracts 78:584606 (1973).
Chemical Abstracts 98:107161d (1983).
Chemical Abstracts 83:131584c (1975).
Chemical Abstracts 84:59400u (1976).
Chemical Abstracts 100:103390q (1984).
Chemical Abstracts 104:109686v (1985).
Chemical Abstracts 104:19499g (1985).
Chemical Abstracts 105:78821z (1986).
Chemical Abstracts 107:236661v (1987).
Chemical Abstracts 108:15674v (1988).
Chemical Abstracts 108:37647r (1988).
Chemical Abstracts 108:150298r (1988).
Chemical Abstracts 109:128816g (1988).
Chemical Abstracts 110:135063h (1989).
Chemical Abstracts 111:153607p (1989).
Chemical Abstracts 112:216577x (1990).
Chemical Abstracts 113:109332n (1990).
Chemical Abstracts 116:262282c (1992).
Chemical Abstracts 59:10006g (1963).
Chemical Abstracts 81:20780e (1974).
Derwent Abstract, C93-164399 (1993).
Leonardi Amedeo
Motta Gianni
Riva Carlo
Testa Rodolfo
Grumbling Matthew V.
Recordati S.A. Chemical and Pharmaceutical Company
Rizzo Nicholas
LandOfFree
Bicyclic heterocyclic derivatives having .alpha..sub.1 -adrenerg does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic heterocyclic derivatives having .alpha..sub.1 -adrenerg, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic heterocyclic derivatives having .alpha..sub.1 -adrenerg will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1359868